DelveInsight’s “Acute Myeloid Leukemia (AML) - Market Insights, Epidemiology and Market Size Forecast-2020” Reports provides an overview of the disease and global market size of the Acute Myeloid Leukemia (AML) for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Acute Myeloid Leukemia (AML) from 2010-2020.Acute myeloid leukaemia (AML) are a type of cancer that affects the blood and bone marrow. AML is characterized by an overproduction of immature white blood cells, called myeloblasts or leukemic blasts. Overall, of all those with AML, around 20 out of 100 people (20%) will survive for 5 years or more after they are diagnosed. Younger people tend to do much better than older people. The reasons for poor survival in older age include the inability to tolerate intensive therapy resulting from concomitant medical illnesses and organ dysfunction, and a greater resistance to therapy as a result of preexisting. The future prognosis demands development of more effective therapies, particularly for elderly patients, would improve survival and increase disease prevalence. AML has the largest pipeline among leukemia’s due to its significant unmet need.
Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management, and current treatment options.
Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.
The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2010-2020.
It also provides Market size of Acute Myeloid Leukemia (AML) for United States, EU5 and Japan from 2010 and forecasted Market size to 2020
Note*: This report requires 5-10 business days to complete.